SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,681 | -8.1% | 60,983 | +0.2% | 0.00% | 0.0% |
| Q2 2023 | $1,829 | -55.4% | 60,860 | -46.3% | 0.00% | -60.0% |
| Q1 2023 | $4,103 | -42.6% | 113,249 | -43.5% | 0.01% | -50.0% |
| Q4 2022 | $7,152 | -99.9% | 200,492 | +2.5% | 0.01% | 0.0% |
| Q3 2022 | $6,619,000 | -5.2% | 195,553 | -19.0% | 0.01% | +11.1% |
| Q2 2022 | $6,985,000 | +118.1% | 241,519 | +143.8% | 0.01% | +200.0% |
| Q1 2022 | $3,202,000 | +6.2% | 99,066 | -4.2% | 0.00% | 0.0% |
| Q4 2021 | $3,016,000 | +55.7% | 103,444 | +42.4% | 0.00% | +50.0% |
| Q3 2021 | $1,937,000 | -14.1% | 72,622 | -0.9% | 0.00% | 0.0% |
| Q2 2021 | $2,256,000 | +13.5% | 73,261 | -3.5% | 0.00% | 0.0% |
| Q1 2021 | $1,988,000 | +4.0% | 75,948 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,911,000 | +20.7% | 75,948 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,583,000 | -3.3% | 75,948 | +10.2% | 0.00% | 0.0% |
| Q2 2020 | $1,637,000 | +39.8% | 68,914 | +5.9% | 0.00% | 0.0% |
| Q1 2020 | $1,171,000 | +11.4% | 65,064 | +46.9% | 0.00% | +100.0% |
| Q4 2019 | $1,051,000 | -24.9% | 44,300 | -13.0% | 0.00% | -50.0% |
| Q3 2019 | $1,399,000 | -79.7% | 50,900 | -75.6% | 0.00% | -77.8% |
| Q2 2019 | $6,889,000 | -1.0% | 208,201 | +4.8% | 0.01% | 0.0% |
| Q1 2019 | $6,962,000 | +7.0% | 198,684 | +1.4% | 0.01% | 0.0% |
| Q4 2018 | $6,507,000 | -36.5% | 195,884 | -3.7% | 0.01% | -25.0% |
| Q3 2018 | $10,245,000 | -26.8% | 203,484 | -13.0% | 0.01% | -29.4% |
| Q2 2018 | $13,992,000 | +44.2% | 233,782 | +10.3% | 0.02% | +41.7% |
| Q1 2018 | $9,704,000 | +0.2% | 211,882 | -12.8% | 0.01% | 0.0% |
| Q4 2017 | $9,685,000 | -6.4% | 243,037 | -6.0% | 0.01% | -7.7% |
| Q3 2017 | $10,347,000 | -22.7% | 258,676 | -16.7% | 0.01% | -27.8% |
| Q2 2017 | $13,390,000 | +42.3% | 310,665 | +3.3% | 0.02% | +38.5% |
| Q1 2017 | $9,410,000 | +17.8% | 300,630 | -5.0% | 0.01% | +18.2% |
| Q4 2016 | $7,990,000 | +16.3% | 316,430 | +13.9% | 0.01% | +10.0% |
| Q3 2016 | $6,871,000 | +25.1% | 277,850 | +3.1% | 0.01% | +25.0% |
| Q2 2016 | $5,492,000 | +46.1% | 269,600 | +9.4% | 0.01% | +33.3% |
| Q1 2016 | $3,758,000 | +35.8% | 246,439 | +19.6% | 0.01% | +50.0% |
| Q4 2015 | $2,768,000 | -0.7% | 205,981 | +3.7% | 0.00% | 0.0% |
| Q3 2015 | $2,788,000 | -14.3% | 198,682 | +3.7% | 0.00% | -20.0% |
| Q2 2015 | $3,255,000 | – | 191,669 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |